Every Cure

01/23/2026

01/08/2026

We are proud to announce that Every Cure is launching a new drug repurposing program focused on DFMO for Bachmann–Bupp Syndrome, an ultra-rare genetic condition that has been identified in only about 20 children worldwide.

Children with Bachmann–Bupp Syndrome often require feeding tubes, have limited motor control, and face significant daily challenges. The condition was first described by Dr. Bachmann and Dr. Bupp, who also pioneered the use of DFMO—a drug originally developed to treat African sleeping sickness—to target the underlying biology of this disease. In treated patients, DFMO has shown the potential to reverse key symptoms, including removing feeding tubes and helping children sit up and interact more fully with their families.

So far, approximately six children have been treated with DFMO, with meaningful improvement observed in five of them. This is exactly the kind of condition that is often overlooked because of its rarity and exactly why drug repurposing matters.

We are deeply grateful to Drs. Bachmann and Bupp for their groundbreaking work, and we are honored to partner with them to identify more patients, expand access to treatment, and help unlock better outcomes for children and families living with this devastating condition.

Click the link below to read the full press release!
https://newsroom.corewellhealth.org/news-releases?item=125205

12/31/2025

Today we’re excited to reveal 2025 Every Cure Discovery Wrapped!

This year, our AI reviewed 39,284,922 potential drug–disease matches — and our team of scientists rolled up their sleeves to manually evaluate 9,302 of the most promising ones. Together, we explored nearly 88 million data points across our biomedical knowledge graphs, spanning 9.23M nodes and 77.17M edges, all with one goal: finding cures hiding in plain sight.

We collaborated with incredible partners across academia, industry, and tech — and yes, we even shipped code to production with zero bugs.

Here’s to 2026, and to every patient still waiting.

12/03/2025

The lesson of this video is that if you have a rare disease, you need to go to the most experienced centers because in my case even the bus driver could tell I was a Castleman Disease patient when top doctors at other hospitals couldn’t!

12/02/2025

In 2024, Joseph was told he had two choices: die in the hospital or die at home.

Instead, a combination of 3 repurposed drugs identified by our team saved his life.

Every Cure is a nonprofit, and the only way we can continue discovering and delivering these lifesaving repurposed treatments is through your support.

His story is powerful, but it represents something far bigger: there are millions of patients just like Joseph who still don’t have a cure, even though the medicines that could help them may already exist.

On this Giving Tuesday, I hope you’ll go to EveryCure.org/donate as it directly fuels the work that gives patients like Joseph another chance.

11/27/2025

Just days after I arrived at Georgetown, my dad called to tell me my mom had brain cancer.

I rushed home, and within 48 hours she was in a 4.5-hour awake brain surgery — the kind where they open your skull and wake you up mid-procedure so they don’t remove too much and affect your ability to speak.

My sisters, my dad, and I were terrified, just waiting for word that she made it through.

When we finally walked into her room, her head wrapped and a drain bulb beside her, she looked right at us, pointed to her bandage, and said, “Chiquita banana lady.”

After everything she had just endured, her first instinct was to make us laugh.

That moment said everything about who she was — strength, humor, and love all wrapped together.

11/26/2025

11/21/2025

11/19/2025

Hydroxychloroquine and everolimus might stop breast cancer from coming back!

A new Nature Medicine study from Drs. Angela DeMichele and Lewis A. Chodosh at the University of Pennsylvania found that everolimus and hydroxychloroquine—two medicines already approved for other conditions—can dramatically reduce the dormant tumor cells that often cause recurrence.

In this small clinical trial, the combination of both drugs led to an 87% drop in dormant tumor cells and 100% recurrence-free survival at three years for the treated patients.

This is a major step toward targeting cancer before it returns—and a powerful reminder that some of the most promising cures might already be sitting on pharmacy shelves.


25m